Cosmetic cross-reference Noindex: medium evidence

Propolis, Ext.

CAS 85665-41-4

Propolis, Ext. (CAS 85665-41-4) is a pharmaceutical compound with 0 bioactivity targets and 1 adverse event association.

SOURCE NLM DailyMed

Label records

0

SOURCE EMBL-EBI ChEMBL

Bioactivity

0

SOURCE DrugCentral

Adverse signals

1

SOURCE IUPHAR/BPS

PubMed IDs

0

SOURCE EPA DSSTox

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Propolis, Ext.

CAS Number

85665-41-4

Source Match

EPA DSSTox

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE DSSTox identifiers DTXSID101042812

Cross-Reference to Chemicals

Same-CAS substance identity is available in the industrial chemicals vertical.

PROPOLIS, EXT. is linked to DTXSID101042812 in DSSTox identifiers.

View industrial chemical data →

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Propolis, Ext. used for in pharmaceutical contexts?

Propolis, Ext. (CAS 85665-41-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Propolis, Ext.?

Propolis, Ext. has 1 DrugCentral/FAERS adverse event association. Rendered reaction terms include Death. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Propolis, Ext. also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Propolis Extract with EU status "permitted".

What clinical phase is Propolis, Ext. in?

No phase 1-4 clinical development badge is rendered for Propolis, Ext. because the matched compound identifier rows do not contain a max-phase value.